Monitoring Response to Therapeutic Interventions in Patients With Cancer
Section snippets
Methodological Considerations
Therapy monitoring requires a high level of standardization and reproducibility of imaging because it aims to assess changes in tracer uptake during a period of weeks to months.5, 11 Additionally, imaging signals can only serve as a surrogate endpoint if the results correlate with clinical outcome and patient survival. In contrast to morphologic parameters, biologic imaging markers are subject to considerable inter- and intraindividual variability and thus are more susceptible to physiologic
Therapy Monitoring with 18F-FDG-PET/CT
Numerous clinical studies have evaluated the role of FDG-PET for assessment of early and late therapy response (Table 1, Table 2), tumor control, and prediction of prognosis. Especially the evaluation of response to therapy appears to be one of the most promising future indications for 18F-FDG-PET/CT imaging in clinical routine. The following section gives an overview of the role of 18F-FDG-PET/CT in the assessment of therapy response and prognosis, with special emphasis on early therapy
Therapy Monitoring with 18F-FLT-PET
PET with the use of the glucose analog FDG is an established imaging modality for predicting tumor response to therapy and patient survival.145 However, FDG is not tumor specific and can also accumulate in inflammatory lesions such as tuberculosis (granulomas), inflammation, and sarcoidosis, reducing its specificity and diagnostic accuracy.146, 147 For assessment of proliferative activity and better differentiation of inflammation from malignant tissue, measurement of tumor growth and DNA
Therapy Monitoring with Hypoxia Tracers
PET and PET/CT offer the possibility of in vivo mapping of regional tumor hypoxia with adequate anatomic resolution as well as monitoring of therapy through follow-up mapping of hypoxia. Derivatives of misonidazole—an azomycin-based hypoxic cell sensitizer that was introduced in radiation oncology decades ago—have been successfully labeled with positron emitters. FMISO is a radiopharmaceutical directly derived from misonidazole and is the most extensively studied PET agent for hypoxia mapping
Outlook
Despite the very promising results of recently published and ongoing trials evaluating the role of FDG-PET for response assessment, future validation of FDG-PET/CT for monitoring tumor response is mandatory. From our perspective, the following main aspects should be the focus of future research activities: (1) randomized multicenter trials and standardization of response assessment by PET and (2) assessment and evaluation of oncologic therapies employing new imaging probes.
The MUNICON trial was
Acknowledgments
We appreciate the excellent contributions made by our colleagues PD Dr. Andreas Buck, PD Dr. Ambros Beer, PD Dr. Hinrich Wieder, Dr. Michael Souvatzoglou, and Mrs. Christine Praus.
References (187)
- et al.
RECIST revisited: A review of validation studies on tumour assessment
Eur J Cancer
(2006) - et al.
Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma
J Thorac Cardiovasc Surg
(2004) - et al.
Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendationsEuropean Organization for Research and Treatment of Cancer (EORTC) PET Study Group
Eur J Cancer
(1999) - et al.
X-ray-based attenuation correction for positron emission tomography/computed tomography scanners
Semin Nucl Med
(2003) - et al.
[18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung
Neoplasia
(2005) - et al.
Biological correlates of FDG uptake in non-small cell lung cancer
Lung Cancer
(2007) - et al.
Comparison of simplified quantitative analyses of FDG uptake
Nucl Med Biol
(2000) - et al.
Partial volume correction strategies in PET
PET Clinics
(2007) - et al.
Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer
Ann Oncol
(2002) - et al.
Early, intermediate and advanced Hodgkin's lymphoma: Modern treatment strategies
Ann Oncol
(2007)
Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials
Ann Oncol
[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: An early prognostic tool for predicting patient outcome
Blood
FDG-PET in the clinical management of Hodgkin lymphoma
Crit Rev Oncol Hematol
FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma
Blood
FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma
Ann Oncol
Positron emission tomography in non-Hodgkin's lymphoma: Assessment of chemotherapy with fluorodeoxyglucose
Blood
The role of FDG-PET scans in patients with lymphoma
Blood
Follicular lymphoma international prognostic index
Blood
Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma
Ann Oncol
Early positron emission tomography (PET) restaging: A predictive final response in Hodgkin's disease patients
Ann Oncol
Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma
Blood
Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: A meta-analysis
Lancet Oncol
PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: The MUNICON phase II trial
Lancet Oncol
Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy
Eur J Cancer
Positron emission tomographic scanning predicts survival after induction chemotherapy for esophageal carcinoma
Ann Thorac Surg
Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer
Ann Thorac Surg
European Organisation of Research and Treatment of Cancer (EORTC) Gastrointestinal Group: Workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer
Eur J Cancer
Reporting results of cancer treatment
Cancer
New guidelines to evaluate the response to treatment in solid tumorsEuropean Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
J Natl Cancer Inst
Positron emission tomography as an imaging biomarker
J Clin Oncol
Monitoring cancer treatment with PET/CT: Does it make a difference?
J Nucl Med
Technology insight: Novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs
Nat Clin Pract Oncol
Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer
J Clin Oncol
Positron emission tomography in non-small-cell lung cancer: Prediction of response to chemotherapy by quantitative assessment of glucose use
J Clin Oncol
Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction
J Nucl Med
Monitoring chemotherapy and radiotherapy of solid tumors
Eur J Nucl Med Mol Imaging
A combined PET/CT scanner for clinical oncology
J Nucl Med
Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0
J Nucl Med
Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials
J Nucl Med
High variation in standardized uptake values among PET systems from different manufacturers
J Nucl Med Meeting Abstracts
Acquisition protocol considerations for combined PET/CT imaging
J Nucl Med
Four-dimensional (4D) PET/CT imaging of the thorax
Med Phys
Attenuation correction of PET images with respiration-averaged CT images in PET/CT
J Nucl Med
Local motion correction for lung tumours in PET/CT-first results
Eur J Nucl Med Mol Imaging
To enhance or not to enhance?18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT
J Nucl Med
Misalignment in PET/CT: relevance for SUV and therapy management
Nuklearmedizin
18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression
J Nucl Med
18FDG uptake in oesophageal adenocarcinoma: Linking biology and outcome
J Cancer Res Clin Oncol
Imaging of tumor glucose utilization with positron emission tomography
Cancer Metastasis Rev
An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development
Cancer Res
Cited by (27)
Multi-technique hybrid imaging in PET/CT and PET/MR: What does the future hold?
2016, Clinical RadiologyCitation Excerpt :Clinical adaption of FDG PET/CT in assessing response to treatment in solid tumours has been trailing behind compared to haematological tumours. Promising results have been published for FDG PET/CT-guided response monitoring in solid tumours, including identification of patients not responding to treatment as early as 2 weeks after start of therapy in numerous tumour entities including lung, oesophageal, gastric, colorectal, sarcoma, and breast cancer51,52; however, the lack of prospective, randomised, multicentre studies and established PET/CT response criteria has delayed the translation into the clinical routine. The introduction of the PET Response Criteria in Solid Tumours (PERCIST) criteria by Wahl and colleagues addressed the limitation of standardised reporting criteria.53
Positron emission tomography-computed tomography versus positron emission tomography-magnetic resonance imaging for diagnosis of oral squamous cell carcinoma: A pilot study
2015, Journal of Cranio-Maxillofacial SurgeryCitation Excerpt :PET–CT has been recommended for staging, distant and micro-metastasis detection, relapse, and cancer of unknown primary detection as well as IMRT planning (Reske and Kotzerke, 2001). Relapse is usually found within the first 2 years after diagnosis, and morphological information from MRI or CT scans might be difficult to interpret in many cases (Herrmann et al., 2009; Hustinx and Lucignani, 2010; Levine et al., 2011; Yaghmai et al., 2011). The latest development in the field of PET was the establishment of PET–MRI, providing metabolic information together with superior soft tissue contrast of MRI (Antoch and Bockisch, 2009).
Evaluation of the SUV values calculation and 4D PET integration in the radiotherapy treatment planning system
2011, Radiotherapy and OncologyThe role of adaptive and functional imaging modalities in radiation therapy: Approach and application from a radiation oncology perspective
2010, Seminars in Ultrasound, CT and MRICitation Excerpt :One final use for functional imaging studies in oncology is their role in assessing response to therapy. Studies may be performed early in the course of treatment to monitor treatment efficacy and dictate potential shifts in underperforming strategies.130,146-151 On other occasions, they are used at the end of treatment to determine appropriateness of further therapeutic interventions.
Influence of chemoresistance and p53 status on fluoro-2-deoxy-d-glucose incorporation in cancer
2010, Nuclear Medicine and BiologyThe use of PET/MRI in radiotherapy
2024, Insights into Imaging